Backgrounds/Aims: Primary hepatic neuroendocrine tumours (PHNETs) are a rarity and this rarity imparts management complexities. Methods: A retrospective analysis of prospectively maintained liver database from 2009 to 2018 was performed and patients with PHNETs were identified and studied for clinical, imaging and pathological features, surgical outcomes, disease free and overall survival. Results: Thirteen patients of PHNET were identified following rigorous investigational protocols, which constituted 0.6% of all liver tumours (2095) in our series. The median age of patients was 50 years (14-65), with male to female ratio of 9:4. Eight patients (62%) underwent hepatic resections as primary treatment, while 5 (38%) patients received peptide receptor radiotherapy, trans-arterial chemotherapy, trans-arterial radiotherapy or a combination of these. In the surgical group at a median follow up of 36 months (range 5-114 months), 4 (50%) patients were alive without disease and disease free survival was 20 months. Median OS in surgical group was 47 months (40-53, 95% confidence interval) that was better but not statistically significant from that of non-surgical treatment group (36 months). Conclusions: PHNETs are rare tumours that require multidisciplinary treatment approach. Liver directed surgery centred management leads to better clinical outcomes in these selected patients. (Ann Hepatobiliary Pancreat Surg 2020;24:17-23)
INTRODUCTION
Primary hepatic neuroendocrine tumours (PHNETs) were described by Edmondson in 1958. 1 They are rare primary hepatic tumours that constitute 0.3% of all neuroendocrine tumours, with fewer than 150 cases reported in literature till date. 2, 3 PHNET is a diagnosis of exclusion and evaluation continues over pre-operative, intra-operative and post-operative period, being a diagnosis in continuum. 3 The picture is further complicated by nonspecific clinical features and overlapping imaging features with other common primary and metastatic liver cancers. 2 Although clinical features and imaging characteristics have been explained in detail in various case series, information is scarce with respect to treatment options and survival outcomes. [1] [2] [3] We have reviewed the clinical data of patients with PHNETs to study the clinical presentations, imaging features, treatment options and survival outcomes.
MATERIALS AND METHODS
A retrospective analysis of prospectively maintained 
RESULTS

Demographics and clinical features
PHNETs constituted 0.6% of all the liver tumours in our database, with a median age of 50 years (range 14-65 years) and a male: female ratio of 9:4. In our series, the clinical presentation was abdominal pain in 5 (38%) patients, incidental in 5 (38%) and 3 (24%) patients had diarrhoea and breathlessness as the predominant symptom.
One of the patients had underlying primary biliary cirrhosis and one was previously treated for cervical cancer (Table 1) . Tumour characteristics, pre-operative diagnosis and treatment strategies Three patients (23%) had bilobar involvement. Four pa- Grade III poorly differentiated NEC in 2 (25%) patients.
Tumour markers and imaging findings
Overall well differentiated NETs Grade I and II was seen in 2 (15%) and 9 (70%) patients respectively, while poorly differentiated NEC was seen in 2 (15%) patients. Mitotic index and Ki67 index was in coherence for all patients. In our study group, 4 patients were considered inoperable. All patients had bilobar disease with multiple lesions and median cumulative size of 15 cm (14 cm-18 cm).
Median Chromogranin A levels were 10000 ng/L (range 9000-10933 ng/L). Well differentiated NETs Grade I and II was seen in 1 (25%) and 3 (75%) patients respectively.
Out of 4 (30%) patients, 1 (25%) underwent peptide receptor radiotherapy (PRRT) alone, 2 (50%) underwent TACE followed by PRRT and one (25%) underwent trans-arterial radioembolisation (TARE) ( Table 2 ).
Follow up, recurrence rates and survival analysis Follow up was conducted in standardised manner as de- wasn't statistically significant (Fig. 2) .
DISCUSSION
PHNETs are extremely rare (less than 0.3% of all neuroendocrine tumours) and hence difficult to diagnose and treat. 1 Based on the available literature mean age of presentation is between 4th and 5th decade with no definite gender predominance. In this study mean age was 50 years (range: 14-65 years) with male to female ratio of Presentation is predominantly non-specific with pain being the most common symptom in 65% of patients and features of carcinoid syndrome being extremely rare. In Traditional tumour markers like CA 19-9, AFP and CEA are not raised in majority of patients, however we found that 24% patients had marginally raised CA 19-9 levels but levels were less than 3 times the normal levels and in all patients it returned to normal after treatment.
Being functionally deficient, we believe 5-HT and HIAA levels would have very low sensitivity in PHNETs.
However, sensitivity and specificity of chromogranin A is high (90 and 92%) and can be used in monitoring disease progress5. Chromogranin A levels were raised in all of our patients and were used to monitor the treatment on follow up with high accuracy in predicting recurrence and response. In our series accuracy of pre-operative biopsy was 77% which is much higher than 57% as reported by Hwang et al. 5 Although post resection histopathology serves as the main method of final diagnosis, we are of the opinion that pre intervention diagnosis should be established in all the patients given the high survival potential even in un-resectable group when treated by appropriate non-surgical interventions. [6] [7] [8] [9] The imaging characteristics of PHNETs lack specificity making it difficult to differentiate from other common solid or cystic lesions of the liver. 10 
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Both 68 Ga-DOTA-TOC (Sensitivity 93%, Specificity 85%) and 68 Ga-DOTA-TATE (Sensitivity 96%, Specificity 100%) have high sensitivity and specificity for diagnosing NETs on PET scan. Fusion scan provide information regarding diagnosis, treatment planning, follow-up and aid in ruling out any extra hepatic disease. 13 We used 15 and Iwo et al. 16 respectively. The recurrence rate of 50% in this series is higher than that 18-20% reported in other series. On survival curve analysis, separation of curves was obtained between different grades and Ki67 indices but was statistically non-significant (Fig. 2) . Survival was better in patients with Ki 67 index less than 15%. Hwang et al. in his study found that Ki-67 index is the predictor of prognosis and tumour recurrence. 5 In our study there was no extra hepatic involvement, while other studies showed a collective extra hepatic involvement in 19%. 13 Overall, surgical resection is effective, safe and prognosis is excellent despite high recurrence rate 8. Table 3 compares variables of major studies on PHNETs with that of present study.
This study has limitations inherent to a retrospective design and an extremely rare disease. Some analytical data may not be representative in view of small sample size.
However, this study series does add some vital aspects regarding demography, clinical features, imaging features, treatment options and outcome of this rare disease.
PHNET is an extremely rare NET that predominates in middle-aged population and presents as non-specific ab- 
